Alnylam Pharmaceuticals (NASDAQ:ALNY) EVP Sells $523,584.70 in Stock

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) EVP Tolga Tanguler sold 1,598 shares of the company’s stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $327.65, for a total value of $523,584.70. Following the completion of the transaction, the executive vice president owned 36,606 shares in the company, valued at $11,993,955.90. This represents a 4.18% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

Tolga Tanguler also recently made the following trade(s):

• On Friday, February 13th, Tolga Tanguler sold 1,959 shares of Alnylam Pharmaceuticals stock. The stock was sold at an average price of $310.08, for a total value of $607,446.72.
• On Monday, January 12th, Tolga Tanguler sold 1,510 shares of Alnylam Pharmaceuticals stock. The shares were sold at an average price of $362.87, for a total value of $547,933.70.

Alnylam Pharmaceuticals Trading Up 2.7%

Shares of Alnylam Pharmaceuticals stock traded up $8.65 during trading hours on Wednesday, hitting $327.30. The company’s stock had a trading volume of 931,139 shares, compared to its average volume of 1,481,848. The stock has a market cap of $43.41 billion, a price-to-earnings ratio of 191.40 and a beta of 0.36. The company has a debt-to-equity ratio of 1.28, a quick ratio of 2.71 and a current ratio of 2.76. Alnylam Pharmaceuticals, Inc. has a twelve month low of $205.87 and a twelve month high of $495.55. The firm has a fifty day moving average of $357.29 and a 200-day moving average of $417.03.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings data on Thursday, February 12th. The biopharmaceutical company reported $1.25 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.43 by ($0.18). Alnylam Pharmaceuticals had a net margin of 6.43% and a return on equity of 69.02%. The company had revenue of $1.10 billion during the quarter, compared to analysts’ expectations of $1.16 billion. During the same quarter last year, the firm posted ($0.65) earnings per share. The firm’s quarterly revenue was up 84.9% on a year-over-year basis. Research analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Institutional Investors Weigh In On Alnylam Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Groupama Asset Managment increased its position in Alnylam Pharmaceuticals by 160.4% in the 3rd quarter. Groupama Asset Managment now owns 4,032,082 shares of the biopharmaceutical company’s stock valued at $18,610,000 after acquiring an additional 2,483,697 shares during the period. Norges Bank purchased a new position in shares of Alnylam Pharmaceuticals in the 4th quarter valued at approximately $895,816,000. Arrowstreet Capital Limited Partnership increased its holdings in shares of Alnylam Pharmaceuticals by 698.8% in the third quarter. Arrowstreet Capital Limited Partnership now owns 1,355,609 shares of the biopharmaceutical company’s stock valued at $618,158,000 after purchasing an additional 1,185,909 shares during the period. Qube Research & Technologies Ltd purchased a new stake in shares of Alnylam Pharmaceuticals during the third quarter worth approximately $369,943,000. Finally, Holocene Advisors LP purchased a new stake in shares of Alnylam Pharmaceuticals during the second quarter worth approximately $194,616,000. 92.97% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

ALNY has been the subject of several research reports. Morgan Stanley dropped their price target on shares of Alnylam Pharmaceuticals from $495.00 to $408.00 and set an “equal weight” rating for the company in a research note on Friday, January 30th. Barclays started coverage on Alnylam Pharmaceuticals in a research note on Wednesday, January 28th. They set an “overweight” rating and a $527.00 target price for the company. Wall Street Zen cut Alnylam Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Saturday, February 14th. Truist Financial cut their target price on shares of Alnylam Pharmaceuticals from $535.00 to $530.00 and set a “buy” rating on the stock in a research note on Thursday, January 8th. Finally, Raymond James Financial reaffirmed an “outperform” rating and issued a $472.00 target price on shares of Alnylam Pharmaceuticals in a report on Monday, January 12th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and five have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $477.96.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.